Search for content, post, videos

Ascelia Pharma achieves major milestone

Magnus Corfitzen
The company has announced the completion of the patient enrollment in the company’s phase 3 clinical study SPARKLE with the lead candidate drug Orviglance. “We are very pleased to have reached our enrollment target of 80 patients in the SPARKLE study within our recently updated timelines. Thi
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.